权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

A Molecular Approach to Prevent Pulmonary Dysfunction in the Intrauterine Growth

预防宫内生长过程中肺功能障碍的分子方法

基本信息

批准号：
7936249
负责人：
VIRENDER K REHAN
金额：
$ 6.85万
依托单位：
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-09-20 至 2012-02-29
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7936249
关键词：
Accounting Adolescent Adult Affect Age Alveolar Alveolus Arts Cells Chronic lung disease Data Development Diabetes Mellitus Epidemiology Epithelial Fetal Growth Fetal Growth Retardation Functional disorder Genes Growth Homeostasis Human Hypertension Immunohistochemistry Infant Intervention Life Lung Mediating Mesenchymal Modeling Molecular Morbidity - disease rate Nutrient Obesity Organ PPAR gamma Pathogenesis Pathway interactions Peroxisome Proliferator-Activated Receptors Phospholipids Pregnancy Prevention Preventive Proteins Pulmonary function tests Rattus Regulator Genes Risk Rodent Model Secondary to Signal Pathway Signal Transduction Staging Stress Structure Techniques Technology Therapeutic Time Translating base design fetal food restriction functional genomics in vivo innovation laser capture microdissection lung development morphometry neonate novel offspring overexpression parathyroid hormone-related protein postnatal prevent programs public health relevance respiratory response surfactant

项目摘要

DESCRIPTION (provided by applicant): Intrauterine growth restriction (IUGR) alters lung development, increasing the risk of respiratory compromise throughout postnatal life. Vertical integration of the cell-molecular mechanism(s) underlying this respiratory compromise offers a powerful functional genomic approach to understand the pathogenesis of chronic lung disease in the IUGR offspring. Since lung development is determined by spatio-temporally specific alveolar epithelial-mesenchymal interactions, we hypothesize that IUGR alters the key alveolar epithelial-mesenchymal signaling pathways that are essential for normal lung development. We propose utilizing a well established rodent model of 50% maternal food restriction (MFR) from day 10 of gestation to term and through postnatal day 21. This model has previously been shown to demonstrate adult-onset obesity, diabetes, and hypertension in the MFR offspring. Now our preliminary data provide clear evidence for failed alveolarization and pulmonary dysfunction in the MFR offspring. Using this model and well established molecular techniques such as lung morphometry, Real-Time-PCR, Western analysis, immunohistochemistry, laser capture microdissection, anti-sense and overexpression studies, and in vivo pulmonary function testing, we will 1) determine the effect of MFR on lung structure and function in the offspring at postnatal days 1 and 21, and months 3 and 9; 2) specifically examine how MFR affects alveolar Parathyroid Hormone-related Protein/Peroxisome Proliferator-Activated Receptor 3 signaling that is known to be essential for normal lung development; and 3) evaluate if alterations in key alveolar epithelial-mesenchymal signaling pathways affected by MFR, and the subsequent lung structural and functional changes, can be normalized by either over-expression or silencing of the key regulatory genes involved. Based on our preliminary data, we expect that, in the lung of the MFR offspring, we will find disruption in molecular pathways that are essential for alveolarization, accounting for the altered lung programming seen in the offspring, hence offering the possibility of prevention and/or reversal of such changes with specific molecular interventions. By exploiting the functional genomic approach, the studies proposed herein will translate into novel and innovative molecular preventive and therapeutic approaches for pulmonary dysfunction seen in IUGR offspring secondary to not only MFR, but also to other causes. PUBLIC HEALTH RELEVANCE: There is accumulating evidence to show that infants who are delivered following growth restriction during the fetal period have significant lung morbidity during their postnatal life. Further, since the mechanism of this lung morbidity is not known, there is no specific intervention to prevent it. Using a well established rat model of intrauterine growth restriction and the state-of-the-art technology, we propose studies that will unravel the fundamental molecular mechanism (s) of pulmonary dysfunction in the growth restricted offspring, allowing us to design novel intervention strategies that may not only prevent, but also reverse intrauterine growth restriction associated lung damage during postnatal life.

描述(由申请人提供)：宫内生长受限(IUGR)改变肺部发育，增加出生后呼吸损害的风险。这种呼吸损害背后的细胞-分子机制的垂直整合(S)为了解宫内发育迟缓后代慢性肺部疾病的发病机制提供了一个强大的功能基因组学方法。由于肺发育是由时空特异性的肺泡上皮-间充质相互作用决定的，我们假设IUGR改变了对正常肺发育至关重要的关键的肺泡上皮-间充质信号通路。我们建议使用一种成熟的啮齿动物模型，即从怀孕第10天到足月以及出生后第21天实行50%的母体食物限制(MFR)。这一模型先前已被证明在MFR子代中表现为成人型肥胖、糖尿病和高血压。现在，我们的初步数据为MFR后代的肺泡化失败和肺功能障碍提供了明确的证据。利用该模型和成熟的分子技术，如肺形态计量学、实时定量-聚合酶链式反应、免疫组织化学、激光捕获显微切割、反义和过表达研究以及体内肺功能测试，我们将1)确定MFR对出生后1天和21天、3个月和9个月的子代肺结构和功能的影响；2)具体研究MFR如何影响已知对正常肺发育至关重要的肺泡甲状旁腺激素相关蛋白/过氧化物酶体增殖物激活受体3信号；3)评估MFR影响的关键肺泡上皮-间充质信号通路的改变，以及随后的肺结构和功能变化，是否可以通过过度表达或沉默相关的关键调控基因来正常化。根据我们的初步数据，我们预计，在MFR后代的肺中，我们将发现对肺泡化至关重要的分子通路的破坏，这是后代肺编程改变的原因，因此提供了通过特定的分子干预来预防和/或逆转这种变化的可能性。通过利用功能基因组方法，本文提出的研究将转化为新的和创新的分子预防和治疗方法，用于IUGR后代中继发于MFR和其他原因的肺功能障碍。与公共卫生相关：有越来越多的证据表明，在胎儿期生长受限后出生的婴儿在出生后的生活中有严重的肺部疾病。此外，由于这种肺部发病率的机制尚不清楚，因此没有专门的干预措施来预防它。利用成熟的宫内生长受限大鼠模型和最先进的技术，我们提出了一些研究，将揭开生长受限后代肺功能障碍的基本分子机制(S)，使我们能够设计新的干预策略，不仅可以预防，而且可以逆转出生后生命中宫内生长受限相关的肺损伤。